The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells

被引:21
作者
Krneta, T. [1 ]
Gillgrass, A. [1 ]
Ashkar, A. A. [1 ]
机构
[1] McMaster Univ, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON L8S 4K1, Canada
关键词
Immunosuppression; tumor-associated macrophages (TAMs); tumor-associated NK cells; tumor microenvironment; LEWIS LUNG-CARCINOMA; HUMAN NK CELLS; HUMAN OVARIAN-CARCINOMA; BREAST-CANCER PATIENTS; REGULATORY T-CELLS; GROWTH-FACTOR-BETA; CLASS-I MOLECULES; TGF-BETA; INDOLEAMINE 2,3-DIOXYGENASE; PROSTAGLANDIN E-2;
D O I
10.2174/156652413804486269
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Numerous reviews in the field of NK cell biology dictate the pivotal role that NK cells play in tumor rejection. Although these cell types were originally described based on their cytotoxic ability, we now know that NK cells are not naturally born to kill. Both cellular interactions and the local environment in which the NK cell resides in may influence its cytotoxic functions. Just as organ specific NK cells have distinct phenotypic and functional differences, the tumor is a unique microenvironment in itself. The NK cells originally recruited to the tumor site are able to stimulate immune responses and aid in tumor destruction but eventually become persuaded otherwise by mechanisms of immunosuppression. Here, we review potential mechanisms and players involved in NK cell immunosuppression. In particular the effects of another innate immune player, macrophages, will be addressed in augmenting immunosuppression of NK cells within tumors. Tumor-associated macrophages (TAMs) are the main regulatory population of myeloid cells in the tumor and are characterized by their ability to promote tumor cell proliferation and metastasis. In addition, they express/release immunoregulatory factors which have been shown to directly inhibit NK cell function. Understanding how these two cell types interact in the distinct tumor microenvironment will allow us to consider therapies that target TAMs to promote enhanced NK cell activity.
引用
收藏
页码:68 / 79
页数:12
相关论文
共 119 条
[1]   The HLA crossroad in tumor immunology [J].
Algarra, I ;
Cabrera, T ;
Garrido, F .
HUMAN IMMUNOLOGY, 2000, 61 (01) :65-73
[2]   ANTI-TRANSFORMING GROWTH-FACTOR (TGF)-BETA ANTIBODIES INHIBIT BREAST-CANCER CELL TUMORIGENICITY AND INCREASE MOUSE SPLEEN NATURAL-KILLER-CELL ACTIVITY - IMPLICATIONS FOR A POSSIBLE ROLE OF TUMOR-CELL HOST TGF-BETA INTERACTIONS IN HUMAN BREAST-CANCER PROGRESSION [J].
ARTEAGA, CL ;
HURD, SD ;
WINNIER, AR ;
JOHNSON, MD ;
FENDLY, BM ;
FORBES, JT .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2569-2576
[3]   Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor [J].
Balsamo, Mirna ;
Vermi, William ;
Parodi, Monica ;
Pietra, Gabriella ;
Manzini, Claudia ;
Queirolo, Paola ;
Lonardi, Silvia ;
Augugliaro, Raffaella ;
Moretta, Alessandro ;
Facchetti, Fabio ;
Moretta, Lorenzo ;
Mingari, Maria Cristina ;
Vitale, Massimo .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (07) :1833-1842
[4]   Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity [J].
Balsamo, Mirna ;
Scordamaglia, Francesca ;
Pietra, Gabriella ;
Manzini, Claudia ;
Cantoni, Claudia ;
Boitano, Monica ;
Queirolo, Paola ;
Vermi, William ;
Facchetti, Fabio ;
Moretta, Alessandro ;
Moretta, Lorenzo ;
Mingari, Maria Cristina ;
Vitale, Massimo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (49) :20847-20852
[5]  
Bastos KRB, 2002, J LEUKOCYTE BIOL, V71, P271
[6]   Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer [J].
Bauernhofer, T ;
Kuss, I ;
Henderson, B ;
Baum, AS ;
Whiteside, TL .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (01) :119-124
[7]   The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes [J].
Bellora, Francesca ;
Castriconi, Roberta ;
Dondero, Alessandra ;
Reggiardo, Giorgio ;
Moretta, Lorenzo ;
Mantovani, Alberto ;
Moretta, Alessandro ;
Bottino, Cristina .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (50) :21659-21664
[8]   The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Mishra, Anjali ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Becknell, Brian ;
Baiocchi, Robert A. ;
Zhang, Jianying ;
Yu, Jianhua ;
Smith, Megan K. ;
Greenfield, Carli N. ;
Porcu, Pierluigi ;
Devine, Steven M. ;
Rotem-Yehudar, Rinat ;
Lozanski, Gerard ;
Byrd, John C. ;
Caligiuri, Michael A. .
BLOOD, 2010, 116 (13) :2286-2294
[9]   Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].
Berger, Raanan ;
Rotem-Yehudar, Rinat ;
Slama, Gideon ;
Landes, Shimon ;
Kneller, Abraham ;
Leiba, Merav ;
Koren-Michowitz, Maya ;
Shimoni, Avichai ;
Nagler, Arnon .
CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051
[10]   The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].
Bingle, L ;
Brown, NJ ;
Lewis, CE .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265